4. Casirivimab and imdevimab antibody cocktail wins EUA in November
Space-filling model of the Fab fragments of the monoclonal antibodies casirivimab (REGN10933, blue) and imdevimab (REGN10987, orange) from Wikipedia.
Developer: Regeneron Pharmaceuticals (NSDQ:REGN)
Description: The cocktail has shown promise in treating patients with mild-to-moderate COVID-19 who face a high risk of developing severe infection or hospitalization. The IV-delivered therapy has shown promise in reducing hospitalizations and emergency room visits for patients at high risk for disease progression.
Regeneron claimed that the monoclonal antibody cocktail is the first treatment to show “statistically significant anti-viral activity” against COVID-19.
President Trump received the drug when hospitalized with COVID-19 in October, later describing it as a “cure.”
Development status: FDA allowed emergency use of the cocktail in Nov. 2020
Next>>
Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tell Us What You Think!
You must be logged in to post a comment.